Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Randomised, Single-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy of Single Pre-Emptive Doses of GW842166X, a Non-Cannabinoid CB2 Receptor Agonist, on Pain Following Third Molar Tooth Extraction.

NCT00444769 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00444769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Randomised, Single-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy of Single Pre-Emptive Doses of GW842166X, a Non-Cannabinoid CB2 Receptor Agonist, on Pain Following Third Molar Tooth Extraction.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
112 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pain